EMJ Gastroenterology 8 [Suppl 1] . 2019

| View in Fullscreen

Journal Info

Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).